Rocket Pharmaceuticals Inc. (RCKT)$2.96

Market Cap: 838.27 MCurrency: USD

Research Snapshot

Static fundamentals, valuation context, and investor signals for Rocket Pharmaceuticals Inc. (RCKT).

HEALTHCARE

BIOTECHNOLOGY

DCF ready

Valuation

-4.0x

EV/FCF, N/A FCF yield

Quality

-80.5%

ROIC, N/A FCF margin

Growth

N/A

5Y sales (revenue) CAGR

Balance sheet

0.0x

Debt/equity, 6.4x current ratio

Superinvestors

Top: Lee Ainslie (0.1%)

Strengths to research

Debt/equity looks manageable at 0.0x.
10 annual periods are available for trend analysis.

Watchouts

No major valuation, balance sheet, or growth watchouts were detected by the static screen.

Annual data: 10 periods

Quarterly data: 24 periods

Stock snapshot: May 25, 2026

Static dataset: May 25, 2026

Quality Scorecard

Build-time composite score for RCKT.

Grade F

/ 100

Peer Comparison

Target stock against 8 market-cap comparable peers.

Heat map: red worst to green best


RCKT Target	Rocket Pharmaceuticals Inc.	$838.3M	-1.5x	-4.0x	-80.5%	N/A	N/A	N/A	N/A	N/A
NUVB	Nuvation Bio Inc.	$808.4M	-7.9x	-4.0x	-58.0%	N/A	-275.7%	N/A	N/A	N/A
PHVS	Pharvaris NV	$1.0B	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRVI	Trevi Therapeutics Inc.	$667.1M	-44.2x	-15.4x	-23.3%	N/A	N/A	N/A	N/A	N/A
MESO	Mesoblast Ltd Spon ADR	$1.4B	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ADPT	Adaptive Biotechnologies Corp.	$1.5B	-35.6x	-29.7x	-27.2%	23.0%	-17.7%	N/A	N/A	N/A
PGEN	Precigen Inc.	$448.7M	-3.1x	-5.7x	-219.7%	-21.3%	-927.6%	N/A	N/A	N/A
ORIC	ORIC Pharmaceuticals Inc.	$405.2M	-5.7x	-3.2x	-33.7%	N/A	N/A	N/A	N/A	N/A
EWTX	Edgewise Therapeutics Inc.	$1.7B	-20.1x	-11.6x	-0.0%	N/A	N/A	N/A	N/A	N/A

Financial Charts

No financial data available for RCKT (annual).

1 superinvestors own RCKT

Current quarter ownership and quarter-over-quarter share changes.

Superinvestor ownership

Fund	Shares	Value	% Portfolio	QoQ Change
Lee Ainslie Maverick Capital	3,567,372	$13M	0.15%	0.0%